Wedbush reiterates Outperform on Rocket Pharmaceuticals; $15 target
Wedbush reiterated an Outperform rating on Rocket Pharmaceuticals and set a $15.00 price target, implying upside of 339.9% versus the Sep 15 close of $3.41.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.